Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253251 · ClinicalTrials.gov registry record
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
A clinical trial of Cancer, sponsored by MiraKind.
- Recruiting
- Registry status
- 15,000
- Enrollment target
- 1
- Study location
NCT02253251 is a study of Cancer that is actively recruiting participants, run by MiraKind. The registered enrollment target is 15,000 participants, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (333% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02253251, a study of Cancer, is actively recruiting participants, sponsored by MiraKind.
- RECRUITING
- Registry status
- 15,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Conditions Studied
Interventions
- GENETIC KRAS-variant and microRNA binding site mutation testing
Study Locations (1)
California
- MiraKind - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2014-09 |
| Est. Completion | 2035-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253251
The ClinicalTrials.gov registry entry for NCT02253251 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (333% higher). The listed sponsor is MiraKind, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which KRAS-variant and microRNA binding site mutation testing is the first listed.
NCT02253251 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02253251 about?
NCT02253251 is a clinical study titled "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment". The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current foc...
What is the current status of trial NCT02253251?
This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 2014-09. Estimated completion is 2035-09.
What conditions does trial NCT02253251 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT02253251?
The interventions under investigation include: KRAS-variant and microRNA binding site mutation testing (GENETIC).
Who is sponsoring clinical trial NCT02253251?
This trial is sponsored by MiraKind, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253251 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.